FDA Approves First CCR5 Inhibitor Maraviroc (August 7, 2007)
The U.S. Food and Drug Administration (FDA) approved Pfizer's maraviroc (Selzentry), which belongs to a new class of antiretrovirals that could provide an alternative for patients who have developed multidrug resistance.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation